323.20SEK+1.89%Mkt Cap: 28.78B SEKP/E: 28.18Last update: 2026-05-13
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medic…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)28.18
P/E (Forward)111.86
PEG—
P/B14.62
P/S14.40
EV/EBITDA—
EV/Revenue13.31
EPS (TTM)11.52
EPS (Forward)2.90
Cash Flow & Leverage
FCF Yield4.03%
FCF Margin58.06%
Operating CF1.43B SEK
CapEx (TTM)10.24M SEK
Net Debt/EBITDA—
Net Debt-2.15B SEK
Technical
SMA 50320.36 (+0.9%)
SMA 200303.73 (+6.4%)
Beta-0.78
S&P 52W Chg24.23%
Avg Vol (30d)207.08K
Avg Vol (10d)170.25K
Technical Indicators
RSI (14)50.1
MACD0.6486
MACD Signal1.1122
MACD Hist.-0.4636
BB Upper337.21 SEK
BB Middle323.89 SEK
BB Lower310.57 SEK
BB Width8.23%
ATR (14)13.28 SEK
Vol Ratio (20d)0.29x
52W Range
165.5079% of range364.40
52W High364.40 SEK
52W Low165.50 SEK
Profitability
Gross Margin97.04%
EBITDA Margin0.00%
Profit Margin51.14%
Oper. Margin14.77%
ROE51.97%
ROA39.70%
Revenue Growth81.80%
Earnings Growth—
Balance Sheet
Debt/Equity0.02
Current Ratio4.78
Quick Ratio4.76
Book Value/Sh22.19 SEK
Cash/Share24.71 SEK
Dividends
Fwd Div Rate2.000 SEK
Trail. Div Rate2.000 SEK
Div. Yield0.62%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateMay 29, 2026
Pay Date—
Ownership
Shares Out.74.32M
Float54.35M
Insiders42.68%
Institutions34.04%
Analyst Consensus
Rating2.8 (Hold)
Target (Mean)301.40 SEK
Target Range240.00 SEK – 355.00 SEK
# Analysts5
Company
Market Cap28.78B SEK
Enterprise Value26.61B SEK
Revenue (TTM)2.00B SEK
Gross Profit1.94B SEK
Net Income (TTM)1.02B SEK
Revenue/Share22.58 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees129
Last Price323.20 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—